News

UCB’s injection therapy Rystiggo (rozanolixizumab-noli) has been granted regulatory approval in Canada for adults with generalized myasthenia gravis (gMG) who test positive for antibodies against the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) proteins. Anti-AChR or anti-MuSK antibodies — self-reactive antibodies that target the body’s own healthy…

More than 500 members of the myasthenia gravis (MG) community are expected at a conference featuring strategies for patient education, advances in science and treatment, and discussions on managing MG. The Myasthenia Gravis Foundation of America (MGFA)’s National Patient Conference, being held March 30-April 1 in Phoenix and virtually, is…

Myasthenia gravis (MG) is associated with a high personal and societal economic burden, due to work engagement and income difficulties, physician visits, hospitalizations, and medications. That’s according to a new study from Germany that analyzed responses from patient surveys on personal burden, as well as data from a claims…

Investigational therapy batoclimab eased disease severity for adults with generalized myasthenia gravis (gMG) in a Phase 3 trial, but the treatment’s developer said it’s not planning to seek regulatory approval of the treatment for gMG in the U.S. Immunovant, a Roivant subsidiary, is instead focused on using the…

A digital tool developed by BioSensics for remotely monitoring myasthenia gravis (MG) symptoms was found to be feasible in a small clinical study. BioDigit MG includes various assessments that can be completed on a tablet, along with wearable sensors to collect information about physical activity and posture…

One year of treatment with inebilizumab eased symptoms and improved daily functioning for people with generalized myasthenia gravis (gMG) positive for antibodies against the acetylcholine receptor (AChR), according to new data from the Phase 3 MINT clinical trial. Amgen, the company developing inebilizumab, will present the new…

Dosing has started in the first group of healthy adults participating in a clinical study of S-1117, a candidate treatment Seismic Therapeutic designed to break down harmful self-reactive antibodies in autoimmune diseases like myasthenia gravis (MG). Running at a single site in Australia, the Phase 1 clinical…

More than two years of treatment with Zilbrysq (zilucoplan) continues to be associated with sustained clinical responses in adults with generalized myasthenia gravis (gMG), according to interim analyses of the long-term Phase 3 RAISE-XT extension study. These new findings, consistent with earlier interim trial analyses, were presented…

Repeated cycles of Rystiggo (rozanolixizumab-noli) do not increase the risk of safety problems in people with generalized myasthenia gravis (gMG), according to a new analysis of clinical trial data. “These results showed that treatment with [Rystiggo] in patients with gMG was well tolerated and that the incidence of…

The U.S. Food and Drug Administration (FDA) has approved the expanded use of Soliris (eculizumab) for treating children with generalized myasthenia gravis (gMG), ages 6 and older, who are positive for antibodies against the acetylcholine receptor (AChR). The infusion therapy marketed by Alexion, AstraZeneca Rare Disease was…